• Browse
• La mia registrazione (login)
• Registrazione (libera)

Pharmaceutical News

• Stanford University To Limit Pharmaceutical Industry Financing Of Continuing Medical Edu ...
  Thu, 28 August 2008
  Stanford University officials on Tuesday plan to announce a new policy under which pharmaceutical and medical device companies no longer will have the ability to select continuing medical education courses that they seek to finance for physicians at the university's School of Medicine, the
• New Cell Removal Technique Could Make Drugs Cheaper
  Thu, 28 August 2008
  A new method to remove dead cells from the cell cultures that are routinely used to manufacture protein-based drugs has been developed by researchers at the University of Edinburgh. Protein-based drugs are ever more being prescribed to treat various diseases. To produce these drugs, it is usually most efficient to h ...
• Finalists Nominated For The 2008 European Biotechnica Award
  Thu, 28 August 2008
  The three finalists of the 2008 EUROPEAN BIOTECHNICA AWARD have been determined. The biotechnology companies nominated are Cambridge-based Astex Therapeutics Limited (UK), GENEART AG from Regensburg (Germany) and immatics biotechnologies GmbH based in TÃbingen (Germany). The prize, worth EUR 100,000, is awarded to innovative ...
• Manhattan Research Announces Top 10 Product Sites Visited By Physicians
  Thu, 28 August 2008
  Diabetes treatment brand sites from Januvia, Actos, Byetta, and Avandia are among the top pharmaceutical product websites in terms of primary care physician visitation, according to a new from pharmaceutical and healthcare market research company Manhattan Research (www.manhattanresearch.com). Breaking into this year's ...
• Anthera Pharmaceuticals Advances Global Development Strategy For Varespladib In Patients ...
  Wed, 27 August 2008
  Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced the initiation of the FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial designed to examine the impact of ...
• New Trial To Evaluate Nexavar As Adjuvant Therapy In Liver Cancer
  Wed, 27 August 2008
  Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. announced the start of a Phase III study with Nexavar (sorafenib) tablets in liver cancer. The randomized, double-blind, placebo-controlled study is evaluating Nexavar as an adjuvant therapy for patients with hepatocellular carcinoma (HCC), or primary live ...
• Bayer HealthCare And Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement In Vi ...
  Wed, 27 August 2008
  Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that patients with wet age-related macular degeneration (AMD) receiving VEGF Trap-Eye in a Phase 2 extension study on a PRN (as needed) dosing schedule continued to show highly significant improvements at 52 weeks in the primary and key secondar ...
• Patients Taking Cymbalta Experienced Reduced Chronic Low Back Pain In New Study
  Wed, 27 August 2008
  Data from a new study suggest that Cymbalta (duloxetine HCl) 60-120 mg once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) 24-hour average pain score, compared with placebo.(1) Results from the double-blind, 13-week, placebo-controlled study of 236 patients were presented tod ...
• Society Of Plastics Engineers' 2008 Research Award
  Wed, 27 August 2008
  Dr. Dilhan M. Kalyon, Professor of Chemical Engineering and Director of the Highly Filled Materials Institute at Stevens Institute of Technology, has won the Society of Plastics Engineers' 2008 Research Award (in Memory of John C. Moricoli). Kalyon received his B.Eng. in Chemical Engineering in Ankara, Turkey, and his M. Eng ...
• Research And Markets: The Top 10 World's Leading Pharmaceutical Companies: Pfizer
  Wed, 27 August 2008
  Research and Markets has announced the addition of the The Top 10 World's Leading Pharmaceutical Companies: Pfizer report to their offering. In a highly dynamic and fragmented pharmaceutical market, besieged by intense competition, rapid pace of technological innovations and the uncertainty regarding future government regu ...